0.00
price down icon100.00%   -8.16
after-market 시간 외 거래: 8.02 8.02 +
loading
전일 마감가:
$8.16
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$564.26M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
0.00
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
Value
$0.00
$0.00
1주일 범위
Value
$0.00
$0.00
52주 변동 폭
Value
$0.00
$8.345

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
명칭
Regulus Therapeutics Inc
Name
전화
858-202-6300
Name
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
직원
34
Name
트위터
@regulusrx
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
RGLS's Discussions on Twitter

RGLS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RGLS
Regulus Therapeutics Inc
0.00 564.26M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-27 업그레이드 Wells Fargo Equal Weight → Overweight
2024-08-02 개시 Oppenheimer Outperform
2024-03-18 개시 Leerink Partners Outperform
2018-03-28 개시 B. Riley FBR, Inc. Neutral
2018-01-05 개시 Leerink Partners Outperform
2017-06-13 재확인 Chardan Capital Markets Buy
2017-03-06 재확인 Wedbush Outperform
2017-01-30 다운그레이드 Needham Buy → Hold
2017-01-30 다운그레이드 Wells Fargo Outperform → Market Perform
2016-12-07 재확인 Chardan Capital Markets Buy
2016-11-02 재확인 Needham Buy
2016-07-25 재확인 Chardan Capital Markets Buy
2016-06-28 재확인 Chardan Capital Markets Buy
2016-06-28 재확인 FBR Capital Outperform
2016-06-28 재확인 Needham Buy
2016-06-07 재확인 Chardan Capital Markets Buy
2016-04-13 개시 Chardan Capital Markets Buy
2015-12-04 개시 Wells Fargo Outperform
2015-06-09 개시 Guggenheim Buy
2015-04-21 재개 FBR Capital Outperform
2014-11-24 개시 Deutsche Bank Buy
2014-08-07 재확인 FBR Capital Outperform
2013-08-14 재확인 Needham Buy
모두보기

Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스

pulisher
Jun 05, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 01, 2025

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 28, 2025

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma

May 28, 2025
pulisher
May 28, 2025

Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues

May 28, 2025
pulisher
May 27, 2025

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News

May 27, 2025
pulisher
May 27, 2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener

May 27, 2025
pulisher
May 25, 2025

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha

May 25, 2025
pulisher
May 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView

May 15, 2025
pulisher
May 15, 2025

Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media

May 15, 2025
pulisher
May 14, 2025

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail

May 14, 2025
pulisher
May 14, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World

May 14, 2025
pulisher
May 10, 2025

Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World

May 10, 2025
pulisher
May 09, 2025

Regulus Therapeutics to be Acquired by Novartis - TipRanks

May 09, 2025
pulisher
May 08, 2025

Regulus: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World

May 07, 2025
pulisher
May 06, 2025

Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com

May 06, 2025
pulisher
May 05, 2025

What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World

May 05, 2025
pulisher
May 04, 2025

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire

May 04, 2025
pulisher
May 03, 2025

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus

May 03, 2025
pulisher
May 03, 2025

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN

May 03, 2025
pulisher
May 02, 2025

Taxation With Representation: Goodwin, Haynes Boone - Law360

May 02, 2025
pulisher
May 02, 2025

Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN

May 02, 2025
pulisher
May 01, 2025

Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

May 01, 2025
pulisher
May 01, 2025

Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare

May 01, 2025
pulisher
May 01, 2025

Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN

May 01, 2025
pulisher
May 01, 2025

Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers

May 01, 2025
pulisher
May 01, 2025

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus

May 01, 2025

Regulus Therapeutics Inc (RGLS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
자본화:     |  볼륨(24시간):